Apellis (APLS) CTO awarded 45,220 RSUs, lifting holdings to 116,338 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Apellis Pharmaceuticals reported that Chief Technical Officer Nur Nicholson received a grant of 45,220 shares of common stock on January 28, 2026. The shares were awarded at a price of $0 per share as part of an equity compensation program.
According to the footnote, this award is in the form of restricted stock units that vest 25% each year over four years from the grant date, subject to continued service. Following this grant, Nicholson beneficially owns 116,338 shares of Apellis common stock in direct ownership.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Nicholson Nur
Role
Chief Technical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 45,220 | $0.00 | -- |
Holdings After Transaction:
Common Stock — 116,338 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Apellis (APLS) report for Nur Nicholson?
Apellis reported an equity grant to CTO Nur Nicholson. On January 28, 2026, Nicholson was awarded 45,220 shares of Apellis common stock at $0 per share as part of a restricted stock unit compensation package.
What are the vesting terms of Nur Nicholson’s Apellis (APLS) RSU award?
The restricted stock units vest over four years. The 45,220-unit award granted on January 28, 2026 vests 25% annually on each anniversary of the grant date, conditioned on Nicholson’s continued service with Apellis.
Was the Apellis (APLS) insider award to Nur Nicholson a purchase or a grant?
The transaction was a grant, not an open-market purchase. Form 4 shows transaction code “A” for an acquisition at $0 per share, indicating an equity compensation award of 45,220 restricted stock units to the Chief Technical Officer.